Amgen is focused on advancing transformative medicines with human DNA. In terms of research and development strategy, the company's pipeline closely aligns with areas where important medical needs exist which include oncology as well as cardiovascular diseases, neuroscience (mini-neuropscyhiatric test), bone health etc.
Amgen heavily invests in oncology, believing it to have potential solutions for multiple cancers. Well, the company has an existing pipeline of novel therapies which focus on targeted indications that are related to specific cancer types — either solid tumors or hematologic malignancies. As an example, Amgen's drug KADCYLA (trastuzumab emtansine) has also proven to be very successful in treating HER2 positive breast cancer and warrants such a change as it boosts patient outcomes tremendously.
Amgen also has another major focus in cardiovascular diseases. Amgen's Repatha has emerged as a cornerstone therapy for lowering LDL cholesterol, with studies showing it reduces levels of this lipid by 60% or more. Amgen has made impact here as well, by demonstrating this drug lowers the risk of cardiovascular events, a crucial area when so many at-risk patients seek treatment for common heart conditions.
Neurosciences is another crucial area to Amgen. Seelos Therapeutics Inc: The company studies new therapies for neurological diseases such as Alzheimer's disease and migraine. One recently launched drug, Amgen's Aimovig (erenumab), works in a novel way to prevent migraines and clinical data show that many patients have days with fewer than two migraine attacks per month.
Other significant focus areas remain on bone health. In particular, Amgen's Prolia (denosumab) has shown efficacy in osteoporosis treatment — especially for postmenopausal women — all of which contributed to decreased overall fracture risk. The use of this drug has been well-documented with its routine usage in clinical practice, highlighting Amgen's recently acquired position as a chronic bone disease management player.
Their strategic focus on these therapeutic areas speaks to Amgen's commitment to advancing medical science and enhancing the health of patients. With its extensive research capabilities and resources, Amgen remains an innovator in these areas.
If you want to know more about Amgen's current therapeutic areas, their R&D pipeline development etc., please refer to this detailed Article on Amgen Therapeutic Areas.